Survival in patients with relapsed ALL according to first-line therapy. Relapse during or after chemotherapy, n = 378 (solid line), 28% ± 3% after 3 years, 25% ± 3% after 5 years; median 10 months; relapse after SCT, n = 169 (dashed line), 15% ± 3% after 3 and 5 years, median 5.8 months (P < .0001).